CASI Pharmaceuticals Stock Financials


USD 1.95  0.02  1.02%   

CASI Pharmaceuticals Enterprise Value is most likely to increase significantly in the upcoming years. The preceding year's Enterprise Value was reported at 59.8 Million. The current Invested Capital is estimated to increase to about 80.1 M, while Net Income Per Employee is projected to decrease to (224.7 K).
With this module, you can analyze CASI Pharmaceuticals financials for your investing period. You should be able to track the changes in CASI Pharmaceuticals individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

CASI Pharmaceuticals Most Recent Estimates

EPS Estimate Next Quarter
Diluted Eps
EPS Estimate Current Year
EPS Estimate Next Year
EPS Estimate Current Quarter
Earnings Share
Understanding current and past CASI Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of CASI Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in CASI Pharmaceuticals' assets may result in an increase in income on the income statement.


32.55 Million

The financial analysis of CASI Pharmaceuticals is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for CASI Pharmaceuticals includes many different criteria found on its balance sheet. For example, investors should never minimize CASI Pharmaceuticals' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor CASI Pharmaceuticals' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in CASI Pharmaceuticals.

CASI Pharmaceuticals Cash

Chance Of Financial Distress
Less than 26
CASI Pharmaceuticals has less than 26 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for CASI Pharmaceuticals stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in CASI Pharmaceuticals' official financial statements usually reflect CASI Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of CASI Pharmaceuticals. For example, before you start analyzing numbers published by CASI Pharmaceuticals accountants, it's critical to develop an understanding of what CASI Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of CASI Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CASI Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in CASI Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CASI Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of CASI Pharmaceuticals' management to manipulate its earnings.

CASI Pharmaceuticals Company Summary

CASI Pharmaceuticals competes with Aurora Cannabis, Agilent Technologies, and Acer Therapeutics. CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland. Casi Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 176 people.
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0000895051
RegionNorth America
Business Address9620 Medical Center
IndustryHealth Care
BenchmarkNYSE Composite
Phone240 864 2600
CurrencyUSD - US Dollar
You should never invest in CASI Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of CASI Pharmaceuticals Stock, because this is throwing your money away. Analyzing the key information contained in CASI Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

CASI Pharmaceuticals Key Financial Ratios

Generally speaking, CASI Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from CASI Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of CASI Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that CASI Pharmaceuticals reports annually and quarterly.

CASI Pharmaceuticals Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what CASI Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Consolidated Income(10.77 M)(27.47 M)(45.36 M)(47.51 M)(35.84 M)(36.79 M)
Net Income(10.77 M)(27.47 M)(46.03 M)(48.29 M)(36.65 M)(39.55 M)
Operating Expenses10.75 M27.19 M47.15 M57.16 M59.45 M64.14 M

CASI Pharmaceuticals Key Cash Accounts

Cash flow analysis captures how much money flows into and out of CASI Pharmaceuticals. It measures of how well CASI Pharmaceuticals is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money CASI Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money CASI Pharmaceuticals had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what CASI Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure(934.7 K)(1.13 M)(7.05 M)1.2 M(8.94 M)(9.17 M)
Depreciation Amortization and Accretion117.78 K1.67 M2.58 M3.23 M3.1 M3.34 M
Net Cash Flow or Change in Cash and Cash Equivalents16.4 M40.72 M(30.58 M)3.44 M(18.36 M)(18.84 M)
Issuance Purchase of Equity Shares23.73 M92.27 M3.75 M45.9 M30.48 M31.2 M
Net Cash Flow from Financing23.73 M92.27 M22.05 M47.15 M29.64 M26.82 M
Net Cash Flow from Investing(934.7 K)(21.77 M)(28.06 M)(20.72 M)(20.69 M)(21.24 M)
Net Cash Flow from Operations(6.4 M)(28.58 M)(23.24 M)(25.89 M)(26.84 M)(27.55 M)
Share Based Compensation650.44 K6.12 M7.31 M7.82 M7.77 M6.2 M

CASI Pharmaceuticals Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining CASI Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare CASI Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CASI Pharmaceuticals competition to find correlations between indicators driving CASI Pharmaceuticals's intrinsic value. More Info.
CASI Pharmaceuticals is rated second in target price category among related companies. It is number one stock in shares owned by insiders category among related companies making about  3.27  of Shares Owned by Insiders per Target Price. . Comparative valuation analysis is a catch-all model that can be used if you cannot value CASI Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for CASI Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CASI Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

CASI Pharmaceuticals Systematic Risk

CASI Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. CASI Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on CASI Pharmaceuticals correlated with the market. If Beta is less than 0 CASI Pharmaceuticals generally moves in the opposite direction as compared to the market. If CASI Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one CASI Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of CASI Pharmaceuticals is generally in the same direction as the market. If Beta > 1 CASI Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.

About CASI Pharmaceuticals Financials

What exactly are CASI Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include CASI Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential CASI Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although CASI Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in CASI Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CASI Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as CASI Pharmaceuticals is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of CASI Pharmaceuticals has grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

CASI Pharmaceuticals December 4, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of CASI Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of CASI Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of CASI Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing CASI Pharmaceuticals Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build CASI Pharmaceuticals's daily price indicators and compare them against related drivers.
Information Ratio(0.22)
Maximum Drawdown29.8
Value At Risk(6.72)
Potential Upside6.1
Continue to Trending Equities. You can also try Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for analysis

When running CASI Pharmaceuticals price analysis, check to measure CASI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CASI Pharmaceuticals is operating at the current time. Most of CASI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of CASI Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CASI Pharmaceuticals' price. Additionally, you may evaluate how the addition of CASI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
CEO Directory
Screen CEOs from public companies around the world
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Is CASI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI Pharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
26.5 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine CASI Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.